Manuel Jesús Muñoz

Manuel Jesús Muñoz

Auto-generated profile, based on publicly available information

Manuel Jesús Muñoz

Molecular Biology and Biochemical Engineering Department, Centro Andaluz de Biología del Desarrollo (CABD), University Pablo de Olavide (UPO), CSIC/UPO/JA, Carretera de Utrera Km 1, 41013 Seville, Spain

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMercedes M. Pérez-Jiménez
Mercedes M. Pérez-Jiménez
JMJose Manuel Monje Moreno
Jose Manuel Monje Moreno
ABAna María Brokate-Llanos
Ana María Brokate-Llanos
MVMónica Venegas-Calerón
Mónica Venegas-Calerón
ASAlicia Sanchez-Garcia
Alicia Sanchez-Garcia
MMManuel J. Muñoz
Manuel J. Muñoz
Aging and fertility are two interconnected processes. From invertebrates to mammals, absence of the germline increases longevity. Here we show that loss of function of sul-2, the Caenorhabditis elegans steroid sulfatase (STS), raises the pool of sulfated steroid hormones, increases longevity and ameliorates protein aggregation diseases. This increased longevity requires factors involved in germline-mediated longevity (daf-16, daf-12, kri-1, tcer-1 and daf-36 genes) although sul-2 mutations do not affect fertility. Interestingly, sul-2 is only expressed in sensory neurons, suggesting a regulation of sulfated hormones state by environmental cues. Treatment with the specific STS inhibitor STX64, as well as with testosterone-derived sulfated hormones reproduces the longevity phenotype of sul-2 mutants. Remarkably, those treatments ameliorate protein aggregation diseases in C. elegans, and STX64 also Alzheimer’s disease in a mammalian model. These results open the possibility of reallocating steroid sulfatase inhibitors or derivates for the treatment of aging and aging related diseases.

16 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
IMIsmael Moreno-Sánchez
Ismael Moreno-Sánchez
LHLuis Hernández-Huertas
Luis Hernández-Huertas
DNDaniel Nahón-Cano
Daniel Nahón-Cano
PMPedro Manuel Martínez-García
Pedro Manuel Martínez-García
ATAnthony J. Treichel
Anthony J. Treichel
MMMiguel Moreno-mateos
Miguel Moreno-mateos
CRISPR-Cas13 RNA-targeting systems are widely used in basic and applied sciences. However, its application has recently generated controversy due to collateral activity in mammalian cells and mouse models. Moreover, its competence could be improved in vivo. Here, we optimized transient formulations as ribonucleoprotein complexes or mRNA-gRNA combinations to enhance the CRISPR-RfxCas13d system in zebrafish. We i) use chemically modified gRNAs to allow more penetrant loss-of-function phenotypes, ii) improve nuclear RNA targeting, and iii) compare different computational models and determine the most accurate to predict gRNA activity in vivo. Furthermore, we demonstrate that transient CRISPR-RfxCas13d can effectively deplete endogenous mRNAs in zebrafish embryos without inducing collateral effects, except when targeting extremely abundant and ectopic RNAs. Finally, we implement alternative RNA-targeting CRISPR-Cas systems such as CRISPR-Cas7-11 and CRISPR-DjCas13d. Altogether, these findings contribute to CRISPR-Cas technology optimization for RNA targeting in zebrafish through transient approaches and assist in the progression of in vivo applications.

1 September 1991 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
JSJ. H. Sweiry
J. H. Sweiry
MMM. Munoz
M. Munoz
GMGiovanni E. Mann
Giovanni E. Mann
Transport of cationic amino acids in the isolated perfused rat pancreas was studied using dual-isotope dilution techniques. At 50 microM substrate concentration, unidirectional tracer uptakes for L-arginine (56 +/- 1%), L-lysine (49 +/- 2%), and L-ornithine (44 +/- 3%) were followed by rapid tracer efflux. In the presence of Na+, influx of L-arginine [Michaelis constant (Km) = 1.74 +/- 0.15 mM, maximum velocity (Vmax) = 1.97 +/- 0.07 mumol.min-1.g-1] and L-lysine (Km = 2.48 +/- 0.17 mM, Vmax = 2.42 +/- 0.08 mumol.min-1.g-1) was mediated by a common transport system, sensitive to cis-inhibition by L-ornithine, 2,4-L-diaminobutyric acid, D-lysine, and D-arginine. Substrates for system A [alpha-(methylamino)isobutyric acid] and an anionic carrier (L-aspartate) were poor cis-inhibitors of L-arginine entry. Removal of Na+ resulted in a 40% reduction in cationic amino acid influx. After cell loading (20 min), L-[3H]-lysine cleared predominantly from a slowly exchanging pool with a rate constant of 5.97 +/- 0.67 min. An influx/efflux permeability ratio of 14.5 +/- 1.6 was determined, and efflux of L-lysine was trans-stimulated by vascular challenges with cationic or large neutral amino acids. The specificity, relative Na+ independence, and exchange properties of this saturable cationic amino acid transporter in the pancreatic epithelium resemble those reported for system y+ in cultured fibroblasts and hepatocytes.

8 October 2014 in Genetics
Verified
Journal Article
Closed access
ABAna M Brokate-Llanos
Ana M Brokate-Llanos
JMJose Manuel Monje Moreno
Jose Manuel Monje Moreno
PMPiedad del Socorro Murdoch
Piedad del Socorro Murdoch
MMManuel J Muñoz
Manuel J Muñoz
Type III galactosemia is a metabolic disorder caused by reduced activity of UDP-galactose-4-epimerase, which participates in galactose metabolism and the generation of various UDP-sugar species. We characterized gale-1 in Caenorhabditis elegans and found that a complete loss-of-function mutation is lethal, as has been hypothesized for humans, whereas a nonlethal partial loss-of-function allele causes a variety of developmental abnormalities, likely resulting from the impairment of the glycosylation process. We also observed that gale-1 mutants are hypersensitive to galactose as well as to infections. Interestingly, we found interactions between gale-1 and the unfolded protein response.

23 December 2022 in Foods
Verified
Journal Article
Open access
PDF file
AHAmel Hamdi
Amel Hamdi
IAIsabel Viera Alcaide
Isabel Viera Alcaide
Rafael GuillenRafael Guillen
Rafael Guillen
María Rocío Rodríguez ArcosMaría Rocío Rodríguez Arcos
María Rocío Rodríguez Arcos
MMManuel Jesús Muñoz
Manuel Jesús Muñoz
Ana Jimenez-AraujoAna Jimenez-Araujo
Ana Jimenez-Araujo
Commercial fructans (inulin and oligofructose) are generally obtained from crops such as chicory, Jerusalem artichoke or agave. However, there are agricultural by-products, namely asparagus roots, which could be considered potential sources of fructans. In this work, the fructans extracted from asparagus roots and three commercial ones from chicory and agave were studied in order to compare their composition, physicochemical characteristics, and potential health effects. Asparagus fructans had similar chemical composition to the others, especially in moisture, simple sugars and total fructan contents. However, its contents of ash, protein and phenolic compounds were higher. FTIR analysis confirmed these differences in composition. Orafti®GR showed the highest degree of polymerization (DP) of up to 40, with asparagus fructans (up to 25) falling between Orafti®GR and the others (DP 10–11). Although asparagus fructan powder had a lower fructan content and lower DP than Orafti®GR, its viscosity was higher, probably due to the presence of proteins. The existence of phenolic compounds lent antioxidant activity to asparagus fructans. The prebiotic activity in vitro of the four samples was similar and, in preliminary assays, asparagus fructan extract presented health effects related to infertility and diabetes diseases. All these characteristics confer a great potential for asparagus fructans to be included in the prebiotics market.

27 March 2014 in Biogerontology
Verified
Journal Article
Closed access
PDF file
MPMercedes M. Pérez-Jiménez
Mercedes M. Pérez-Jiménez
MRMaría Jesús Rodríguez-Palero
María Jesús Rodríguez-Palero
EREduardo Ródenas
Eduardo Ródenas
Peter AskjaerPeter Askjaer
Peter Askjaer
MMManuel J. Muñoz
Manuel J. Muñoz